CMRA
Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications. Established in 2014, Comera Life Sciences is headquartered in Woburn, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q3 | -0.10 | $136,310 | -$2M |
| 2023 Q2 | -0.08 | $315,055 | -$999,153 |
| 2023 Q1 | -0.13 | $392,915 | -$2M |
| 2022 Q4 | -0.18 | $156,120 | -$30M |
| 2022 Q3 | -0.20 | $234,922 | -$2M |
| 2022 Q2 | -1.14 | $146,726 | -$3M |
| 2022 Q1 | -0.15 | $95,334 | -$3M |
| 2021 Q4 | -0.11 | $73,334 | -$2M |